Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

Summary

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. We hypothesize that orally administered CGMP has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

Timeline

Start

2012-01

Primary completion

2014-09

Completion

2014-12

Drugs

Indications